Neumora Therapeutics, Inc. (NMRA) Form 10-Q — Aug 14, 2026
Neumora Therapeutics' Q2 2026 10-Q discloses substantial doubt about its ability to continue as a going concern, with $116.8 million in cash that management says will not fund operating plans for at least twelve months from the filing date. The company confirmed it is discontinuing development of navacaprant in major depressive disorder following Phase 3 KOASTAL program results in June 2026, refocusing on NMRA-511 for Alzheimer's disease agitation, NMRA-898 for schizophrenia, and NMRA-215 for obesity and cardiovascular risk.
Key figures
- Total Debt
- 54000000
- Debt Amount
- 60000000
- Cash Position
- 116834000
- Interest Rate
- greater of 10.45% or WSJ prime rate + 2.95%
- Maturity Date
- May 1, 2029
- Shares Outstanding
- 187895912
- Q2 ga expense
- 12907000
- Q2 rd expense
- 29283000
- Atm gross capacity
- 300000000
- Accumulated deficit
- 1280689000
- Stockholders equity
- 44519000
- Six month ga expense
- 27173000
- Six month rd expense
- 67881000
- Atm net proceeds h1 2026
- 20400000
- Q2 rd expense prior year
- 38724000
- K2hv conversion price floor
- 0.8774
- Term loan principal outstanding
- 54000000
- Term loan undrawn milestone tied
- 45000000
- Term loan available discretionary
- 20000000
Price after filing
Close on the filing date to close N calendar days later (from $1.60). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.